Compare GeneDx Holdings Corp (WGS) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? GeneDx Holdings Corp trades at $67.29 (market cap $2.02B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.3 (market cap $560.32M). The key difference: GeneDx Holdings Corp is far larger — about 3.6× Direxion Daily FTSE China Bull 3x Shares's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| WGS | YINN | |
|---|---|---|
Market Cap | $2.02B | $560.32M |
Volume | 734,640 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $167.51 | $52.69 |
52-Week Low | $34.51 | $21.45 |
Typical Hold Time | 19 Days | 25 Days |
Enterprise Value | $2.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
YINN trades at $25.17, up 6.83% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks fundamental financial data disclosure, with key valuation and profitability ratios unavailable. Recent news highlights China's economic policies and export controls, which may influence the fund's underlying holdings.
The outlook is cautious due to bearish technicals and opaque fundamentals. Risks include exposure to Chinese market volatility and regulatory changes. Analyst sentiment is not clearly defined without current consensus data, requiring careful monitoring of emerging financial disclosures and geopolitical developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
